
Protara Therapeutics, Inc. (TARA) Stock Ticker
TARA right now
Market factors today
Unlock the full TARA picture
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
TARA stock facts
| Ticker symbol | TARA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $184.3M |
| CEO | Jesse Shefferman |
| Employees | 46 |
| Headquarters | New York City, NY, US |
| IPO date | 2014-10-22 |
| Website | www.protaratx.com |
What you can see for TARA on Tickr
Live TARA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TARA report.
Rankings
FAQ
What is the ticker symbol for Protara Therapeutics, Inc.?
The ticker symbol for Protara Therapeutics, Inc. is TARA, listed on the NASDAQ Global Market.
What is TARA?
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation…